Platinum-resistant Ovarian Cancer

CLINICAL_TRIALS research · 2026-04-24

Clinical Trial Update: Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer [Phase 1]

Phase 1 trial evaluating adding abemaciclib to olaparib in women with recurrent ovarian cancer, including high-grade serous and platinum-res…

CLINICAL_TRIALS research · 2026-04-21

Clinical Trial Update: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors [Phase 1]

NiKang Therapeutics is conducting a Phase 1 study of NKT3964 in adults with advanced or metastatic solid tumors, and the trial is currently …

CLINICAL_TRIALS research · 2026-04-07

Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]

Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.

CLINICAL_TRIALS research · 2026-03-27

Clinical Trial Update: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors [Phase 1]

Phase 1 trial evaluating HWK-007, a PTK7-directed antibody-drug conjugate, for advanced solid tumors; the study is currently recruiting.

CLINICAL_TRIALS research · 2026-03-18

Clinical Trial Update: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) [Phase 3]

Phase 3 clinical trial evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and Bevacizumab versus physician's choice of ch…

CLINICAL_TRIALS research · 2026-03-13

Clinical Trial Update: A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. [Phase 1]

This clinical trial update outlines a Phase 1 study of HWK-016, a MUC16-directed antibody-drug conjugate, in participants with advanced soli…

CLINICAL_TRIALS research · 2026-03-13

Clinical Trial Update: A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. [Phase 1]

This Phase 1 study is evaluating the safety and potential efficacy of WSK-IM02 in patients with platinum-resistant ovarian cancer, with the …

CLINICAL_TRIALS research · 2026-03-03

Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]

A Phase 3 clinical trial evaluating Rina-S versus investigator's choice in platinum-resistant ovarian cancer; the study is currently active …

CLINICAL_TRIALS research · 2025-12-18

Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer [Phase 1]

A Phase 1 clinical trial to evaluate the safety and efficacy of OPB-101 in platinum-resistant ovarian cancer is ongoing. The study is curren…

CLINICAL_TRIALS research · 2025-08-28

Clinical Trial Update: Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer [Phase 2]

Phase 2 clinical trial update examining etoposide capsules plus bevacizumab, iparomlimab, and tuvonralimab for platinum-resistant or platinu…

CLINICAL_TRIALS research · 2025-07-20

Clinical Trial Update: Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study [Phase 4]

A prospective multicenter Phase 4 trial is assessing the safety and efficacy of combining RIF with Anlotinib in patients with advanced recur…

CLINICAL_TRIALS research · 2025-04-30

Clinical Trial Update: IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

A Phase 2 trial evaluating IN10018 in combination with pegylated liposomal doxorubicin versus PLD with placebo in platinum-resistant recurre…

CLINICAL_TRIALS research · 2025-04-30

Clinical Trial Update: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer [Phase 1, Phase 2]

A Phase 1/2 trial (IN10018) evaluating IN10018 in combination with standard chemotherapy for high-grade serous epithelial ovarian cancer is …

CLINICAL_TRIALS research · 2024-11-25

Clinical Trial Update: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) [Phase 1, Phase 2]

GI Innovation's GI-102 is being studied in a phase 1/2 trial as a single agent and in combination with pembrolizumab or trastuzumab deruxtec…

CLINICAL_TRIALS research · 2024-09-19

Clinical Trial Update: Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer [Phase 2]

Phase 2 trial evaluating Adebrelimab combined with non-platinum chemotherapy and Fuzuloparib for recurrent platinum-resistant ovarian cancer…

CLINICAL_TRIALS research · 2024-08-07

Clinical Trial Update: A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer [Phase 2]

A Phase 2 trial investigating two standard doses of bevacizumab in combination with chemotherapy for epithelial ovarian cancer, including pl…

CLINICAL_TRIALS research · 2024-07-19

Clinical Trial Update: A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

A Phase 2 clinical trial update describes a study of QL1706 combined with albumin-bound paclitaxel and bevacizumab for platinum-resistant re…

Top drugs studied for this disease